Abstract
The study aimed to synthesize and evaluate substituted 4-methyl-2-oxo-2H-chromen-7-yl phenylcarbamates as potent acetylcholinesterase (AChE) inhibitors and anti-amnestic agents. The compounds were evaluated for AChE and butyrylcholinesterase (BuChE) inhibitory activity in rat brain homogenate and plasma, respectively. The most potent test compound 4d was evaluated for memory testing in scopolamine-induced amnesia. The phenylcarbamate substituted coumarins (4a-4h) demonstrated more potent AChE inhibitory as compared to parent 7-hydroxy-4-methylcoumarin. The introduction of phenylcarbamate moiety to coumarin template also significantly increased BuChE inhibitory activity, albeit less than AChE inhibitory activity with approximate BuChE/AChE selectivity ratio of 20. The compound 4d displayed the most potent AChE inhibitory activity with IC50 = 13.5 ± 1.7 nM, along with amelioration of amnesia in mice in terms of restoration of time spent in target quadrant and escap latency time. It is concluded that carbamate derivatives of coumarin may be employed as potential AChE inhibitors and anti-amnestic agents.
Keywords: Phenylcarbamates, coumarin, Alzheimer’s disease, acetylcholinesterase inhibitors.
Medicinal Chemistry
Title:Synthesis and Evaluation of Substituted 4-methyl-2-oxo-2H-chromen-7-yl Phenyl Carbamates as Potent Acetylcholinesterase Inhibitors and Anti- Amnestic Agents
Volume: 9 Issue: 5
Author(s): Preet Anand and Baldev Singh
Affiliation:
Keywords: Phenylcarbamates, coumarin, Alzheimer’s disease, acetylcholinesterase inhibitors.
Abstract: The study aimed to synthesize and evaluate substituted 4-methyl-2-oxo-2H-chromen-7-yl phenylcarbamates as potent acetylcholinesterase (AChE) inhibitors and anti-amnestic agents. The compounds were evaluated for AChE and butyrylcholinesterase (BuChE) inhibitory activity in rat brain homogenate and plasma, respectively. The most potent test compound 4d was evaluated for memory testing in scopolamine-induced amnesia. The phenylcarbamate substituted coumarins (4a-4h) demonstrated more potent AChE inhibitory as compared to parent 7-hydroxy-4-methylcoumarin. The introduction of phenylcarbamate moiety to coumarin template also significantly increased BuChE inhibitory activity, albeit less than AChE inhibitory activity with approximate BuChE/AChE selectivity ratio of 20. The compound 4d displayed the most potent AChE inhibitory activity with IC50 = 13.5 ± 1.7 nM, along with amelioration of amnesia in mice in terms of restoration of time spent in target quadrant and escap latency time. It is concluded that carbamate derivatives of coumarin may be employed as potential AChE inhibitors and anti-amnestic agents.
Export Options
About this article
Cite this article as:
Anand Preet and Singh Baldev, Synthesis and Evaluation of Substituted 4-methyl-2-oxo-2H-chromen-7-yl Phenyl Carbamates as Potent Acetylcholinesterase Inhibitors and Anti- Amnestic Agents, Medicinal Chemistry 2013; 9 (5) . https://dx.doi.org/10.2174/1573406411309050009
DOI https://dx.doi.org/10.2174/1573406411309050009 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resilient Brain Aging: Characterization of Discordance between Alzheimer’s Disease Pathology and Cognition
Current Alzheimer Research Lipid Nanoformulations in the Treatment of Neuropsychiatric Diseases: An Approach to Overcome the Blood Brain Barrier
Current Drug Metabolism AMPK Function in Aging Process
Current Drug Targets Diagnosis and Treatment of Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Endovascular Treatment of Pulmonary and Cerebral Arteriovenous Malformations in Patients Affected by Hereditary Haemorrhagic Teleangiectasia
Current Pharmaceutical Design The Many Faces of Aβ: Structures and Activity
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Chronic Alcohol Abuse and HIV Disease Progression: Studies with the Non-Human Primate Model
Current HIV Research Influence of Hypertension, Alone and in Combination with Other Vascular Risk Factors on Cognition
CNS & Neurological Disorders - Drug Targets Imaging Neuroinflammation in Ischemic Stroke and in the Atherosclerotic Vascular Disease
Current Vascular Pharmacology Neuroprotective Strategies for Neurological Disorders by Natural Products: An update
Current Neuropharmacology Polyphenols and Depression: from Chemistry to Medicine
Current Pharmaceutical Biotechnology APP/PS1 Gene-Environment Noise Interaction Aggravates AD-like Neuropathology in Hippocampus <i>Via</i> Activation of the VDAC1 Positive Feedback Loop
Current Alzheimer Research Arterial Spin Labeling Perfusion MRI in Alzheimers Disease
Current Medical Imaging Analysis of PRKN Variants and Clinical Features in Polish Patients with Parkinson’s Disease
Current Genomics Melatonin-mitochondria Interplay in Health and Disease
Current Topics in Medicinal Chemistry The Co-agonist Site of NMDA-glutamate Receptors: A Novel Therapeutic Target for Age-related Cognitive Decline
Current Pharmaceutical Design Targeting Autophagy in the Brain: A Promising Approach?
Central Nervous System Agents in Medicinal Chemistry Recent Developments in Pharmacologic Prophylaxis of Atrial Fibrillation in Patients Undergoing Surgical Revascularization
Cardiovascular & Hematological Agents in Medicinal Chemistry Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond
Current Pharmaceutical Design